GlassScriptPhysician profile
Stephen B Hillis
NPI 1356314967
$7,521.66
in general payments reported to CMS, 2019-2025
28 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,073 · 2020: $439 · 2021: $518 · 2022: $38.81 · 2023: $197 · 2024: $5,118 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,025 · Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,025.00 |
| Food and Beverage | $428.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rivanna Medical, INC | $5,025.00 | 2024 | Accuro |
| Takeda Pharmaceuticals U.S.A., INC. | $319.38 | 2019-2022 | |
| Amgen INC. | $314.74 | 2019-2020 | |
| Abbvie INC. | $266.57 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $265.62 | 2019-2025 | Farxiga |
| Mayne Pharma Commercial LLC | $239.57 | 2023-2025 | |
| Amarin Pharma, INC. | $166.81 | 2019-2021 | |
| Lilly USA, LLC | $151.59 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $133.24 | 2023 | Jornay Pm |
| Allergan, INC. | $116.72 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $76.43 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.54 | 2021-2022 | |
| Daiichi Sankyo INC. | $43.02 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $41.13 | 2021 | |
| Merck Sharp & Dohme LLC | $34.54 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $33.63 | 2019-2020 | |
| Medtronic Minimed, INC. | $27.38 | 2020 | |
| Greer Laboratories, INC. | $23.92 | 2019 | |
| Genentech USA, INC. | $22.03 | 2020 | |
| Ibsa Pharma INC. | $20.28 | 2019 | |
| Circassia INC. | $19.22 | 2019 | |
| Novo Nordisk INC | $19.08 | 2020 | |
| Seqirus USA INC | $18.26 | 2019 | |
| Shire North American Group INC | $18.21 | 2019 | |
| Currax Pharmaceuticals LLC | $15.13 | 2021 | |
| Pfizer INC. | $14.67 | 2019 | |
| Adlon Therapeutics L.P. | $13.83 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hillis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.